NGPOD improves nasogastric tube safety by reducing the risks of using a misplaced tube. The system was designed in the UK, and NGPOD Global Ltd is headquartered in Runcorn Cheshire, where its global manufacturing is also based.
NGPOD was invited to present because of the partnership we have built with the Tritech team in preparing for a Service Evaluation of the NGPOD System in both Hywel Dda and Swansea Bay HealthBoards that Tritech will lead.
The Service Evaluations will help determine the impact of NGPOD on outcomes for patients and the broader healthcare sector in real-world settings, emphasising Value-Based Healthcare.
NGPOD have partnered with Tritech because of their unique configuration of services that will allow the service evaluations to be completed quickly, rigorously and objectively. This approach is ideal for NGPOD as it has completed its clinical trial and is being commercialised globally. The results of the Service Evaluations will allow clinicians to understand the impact of the product on their organisation without the need to duplicate assessments.
The NGPOD Service Evaluations will take place between January and April 2022.
WHAT IS NGPOD?